VX-765 could be a therapeutic candidate for Alzheimer’s disease.
At CTAD, intranasal insulin trial stumbles, pioglitazone gets a postmortem, a RAGE inhibitor tries to hang on.
At CTAD, researchers discussed baseline data from the first 500 participants in the EPAD cohort and, finally, the start of recruitment for TRC-PAD.
In sporadic and familial forms of AD, progranulin climbs in the cerebrospinal fluid as disease progresses, perhaps reflecting microglial activation.
Bump in the Road or Disaster? BACE Inhibitors Worsen Cognition Second Look at BAN2401 Data Still Positive, Despite Snafu Blood Tests for Amyloid Step Out at CTAD It’s Official: Tau PET Sees Tangles, and Staging Tangles Predicts Decline Amyloid PET Aids ...
In mice, a daily low dose restored regulatory T cells and held off symptoms of a demyelinating disease. Could an old, over-the-counter drug help with ALS, in which similar cells decline?
FDG PET revealed the formation of a new functional brain network. It explains clinical improvements noted previously.
It’s ‘And,’ Not ‘Either-Or’: C9ORF72 Mechanisms of Action are Linked Beyond the Nucleus: TDP-43 Sticks Together, For Better or Worse Going the Distance: FUS Travels to Terminals, Drops Off RNA When RNA transcripts aren’t processed properly or don’t make ...
Scientists say chaperones keep FUS from joining up with aggregating proteins as FUS makes its way down axons to deliver RNAs for local translation. ALS/FTD mutations bungle the process.
At ICFTD in Sydney, researchers update the community on ARTFL/LEFFTDS.
New scales debuted at ICFTD could help clinical trials.
What's the use of measuring neurofilament light in blood? The marker could help with AD trial enrollment and measuring drug effects. It could even guide brain-sparing improvements in heart surgery, say researchers at AAIC 18.
Tau’s apparent lockstep with cognitive decline dominated the PET conversation. Piramal flaunted data, and Merck/Cerveau are close behind. A first stab at imaging synapses in the hippocampus drew notice, too.
In patients across a range of neurodegenerative diseases, NfL ramps up in the cerebrospinal fluid. Levels are higher in those with worse disease.
The awards total $52 million, divided among 17 early career investigators and nine collaborative science teams.